EAS Joint Sessions with ESC and IAS

NLA-EAS joint session: Dyslipidemia Treatment in Light of the New Guidelines

Chair:
  • Lale Tokgözoglu, Turkey
  • Antonio Gotto, USA

Targets and goals: The EAS way

Chris Packard, Glasgow, UK

Targets and goals: The NLA way

Carl E. Orringer, Miami, USA

Therapeutic Approaches: The EAS way

Alberico L. Catapano, Milan, Italy

Therapeutic Approaches: The NLA way

Christie Ballantyne, Houston, USA

ESC-EAS joint symposium: A Deep Dive into ESC/EAS Dyslipidemia Guidelines

Chair:
  • Lale Tokgözoglu, Turkey

How to approach a patient with dyslipidemia without apparent CAD (case by Baris Gencer 5 min) What the guideline says

Victoria Delgado, Leiden, The Netherlands

What is the critical evidence behind the guideline

Brian Ference, Cambridge, United Kingdom

How to approach a patient with dyslipidemia with CAD (case by Anna Lebedeva 5 min) What the guideline says

François Mach, Geneva, Switzerland

What is the critical evidence behind the guideline

Alberico L. Catapano, Milan, Italy

IAS-EAS joint symposium: Celebrating the 60th Anniversary of Atherosclerosis

Chair:
  • Lale Tokgözoglu, Turkey
  • Raul Santos, Brazil

Is Trimethlyamine-N-Oxide (TMAO) a clinically useful biomarker of increased cardiovascular risk?

Arnold von Eckardstein, Zurich, Switzerland

Distribution of macrophage polarization markers in human atherosclerosis

Menno de Winther, Amsterdam, The Netherlands